Related Experiment Video
Updated: Jan 7, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Association of Permanent Atrial Fibrillation With Mortality and Heart Failure Progression in Low Thromboembolic Risk
Kacper Rutkowski1, Bartosz Krzowski1, Paweł Balsam1
11 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
None:
BACKGROUND Although atrial fibrillation (AF) is a well-established risk factor for thromboembolic events, patients with a low CHA₂DS₂-VASc score are generally considered at low risk. However, permanent AF may independently worsen outcomes via non-embolic mechanisms such as myocardial remodeling and progression of heart failure (HF). MATERIAL AND METHODS This retrospective observational sub-study used data from the CRAFT study (NCT02987062), a multicenter registry of AF patients hospitalized between 2011 and 2016. We included 418 patients with CHA₂DS₂-VASc ≤2 for women and with ≤1 for men, of whom 63 had permanent AF as defined by ESC guidelines. The primary endpoint was all-cause mortality; secondary endpoints included ischemic events and bleeding during a mean follow-up of 4 years. RESULTS Patients with permanent AF had significantly higher all-cause mortality (39.7% vs 8.7%; P<0.0001) and a comparable rate of ischemic events (12.7% vs 8.5%; P=0.12) despite similarly low thromboembolic risk profiles. They were older (64 vs 60 years; P<0.0001), more frequently had heart failure (48.4% vs 15.5%; P<0.0001) and, lower left ventricular ejection fraction (LVEF) (43.5% vs 55%; P=0.0005), and more often had cardiac devices. CONCLUSIONS Our findings suggest that permanent AF is associated with worse long-term outcomes, even in patients with low thromboembolic risk score. These results show the importance of early rhythm control in preventing AF progression and irreversible structural remodeling.
More Related Videos
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pathophysiology of Heart Failure
Heart Failure VI: Adjunct Therapies

